Niagen Bioscience Dividend Coverage
Dividend Coverage Ratio of Niagen Bioscience (NAGE) as of Aug 14, 2026.
Get this data via API
Financial Data API
Dividend Coverage
0.00
Last updated:
Dividend Coverage Ratio of Niagen Bioscience is 2026 0.00 . Dividend Coverage Ratio of Niagen Bioscience was 2025 0.00 . It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API
Niagen Bioscience Stock analysis
What does Niagen Bioscience do? The Chromadex Corp was founded in 1999 and is headquartered in Irvine, California. It is a company that specializes in the manufacturing and sale of innovative dietary supplements, pharmaceuticals, and cosmetic products.
Business model:
Chromadex Corp is primarily a research and development company that aims to create innovative products based on the latest scientific findings. The company has acquired numerous patents and licenses that are used in the development of its products. It offers its products directly to consumers as well as to third parties such as health and wellness companies.
Divisions:
The company has three main divisions:
1. ChromaDex Sciences:
This division is involved in the research and development of products and medications based on modern scientific knowledge. ChromaDex Sciences has successful collaborations with renowned institutions such as the University of Mississippi and UC Davis.
2. NutraIngredients-USA:
This division focuses on the distribution of dietary supplements and ingredients that are aimed at improving health and well-being. The company offers a wide range of products, including Tru Niagen, an NAD+ booster product.
3. Analytical Reference Standards:
This division specializes in the manufacturing of reference standards used in scientific research and development. Analytical Reference Standards produces high-quality reference materials and other chemical compounds.
Products:
Chromadex offers a wide range of products. Some of the most well-known products include:
1. Tru Niagen:
Tru Niagen is Chromadex's flagship product. It is an NAD+ booster product that is intended to slow down the aging process. NAD+ is an important chemical compound that our body needs to maintain cell function. When NAD+ is depleted, it can lead to aging-related diseases. Tru Niagen acts as a "molecular booster" and increases the NAD+ level.
2. BluScience:
BluScience was developed by Chromadex to offer a wide range of dietary supplements aimed at improving health and well-being. The product range includes probiotics, vitamins and minerals, and has a broad distribution market in the USA.
3. PUREnergy:
PUREnergy is a natural energy drink developed by Chromadex. It combines caffeine, tea extract, and a special type of ginseng that provides energy over a longer period of time.
Conclusion:
Chromadex Corp is an innovative company specializing in the development of new products in the areas of health, wellness, and pharmaceuticals. It has gained an excellent reputation in the scientific community, particularly through its work in the field of NAD+ research. The wide range of products offered appeals to consumers and the constantly evolving health and wellness markets. Niagen Bioscience is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Niagen Bioscience stock
On Eulerpool you can find the complete historical development of Dividend Coverage Ratio Niagen Bioscience since 2006 – with annual values, charts, and detailed analysis.
The dividend coverage ratio measures how many times dividends can be covered by net income. Higher coverage suggests more sustainable dividend payments.
Dividend Coverage Ratio's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Dividend Coverage Ratio's Niagen Bioscience historically and in real time.
Access this data via the Eulerpool API
Dividend — Niagen Bioscience
All Key Metrics — Niagen Bioscience
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth